"A new consumer-friendly form ( is now available for making reports to MedWatch, the Food and Drug Administration's (FDA) on-line system for collecting information about serious problems with drugs, medical devices and other FDA-"...
(Generic versions may still be available.)
Metrodin® (urofollitropin for injection) stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH, the active component of Metrodin® (urofollitropin for injection) , is the primary hormone responsible for follicular recruitment and development. In order to effect final maturation of the follicle and ovulation in the absence of an endogenous LH surge, human chorionic gonadotropin (hCG) must be given following the administration of Metrodin® (urofollitropin for injection) when monitoring of the patient indicates that sufficient follicular development has occurred. There may be a degree of interpatient variability in response to FSH administration.
The results of the clinical experience and effectiveness of the administration of Metrodin® (urofollitropin for injection) to 173 evaluable patients in 367 completed courses of therapy are summarized below. All patients received prior therapy with clomiphene citrate, without success.
|Patients ovulating|| |
|Patients pregnant|| |
|Patients aborting|| |
|Multiple pregnancies|| |
|Hyperstimulation syndrome (% patients)|| |
* Based on total pregnancies.
** Based on 181 patients who received 446 courses of therapy.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Metrodin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.